Tech-First Companies Take the Lead in AI Drug Discovery
Biopharmaceutical Report II Issue27_August 2023 In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has...
top of page
Search
Companies Making Automated Drug Discovery A Reality
Biopharmaceutical Report I Issue27_August 2023 Data is king in modern biopharmaceutical research, and ability to generate massive amounts...
Artificial Intelligence in Drug Discovery and Biotech; 2022 Recap and Key Trends
Biopharmaceutical Report I Issue26_February 2023 The advent of AI in drug discovery at a glance The current advent of artificial...
17 Companies Building the Future of Drug Development on a Chip
Biopharmaceutical Report II Issue26_February 2023 In the early 2000s, the concept of organ-on-a-chip technology, also known as...
Innovative Value-Based Price Programs Back in the Spotlight
Biopharmaceutical Report I Issue25_December 2021 Value-based plans are emerging as particularly attractive coverage options for therapies...
Upper Middle-Income Countries Left Out by New Merck/Ridgeback COVID-19 Antiviral Licensing Deal
Biopharmaceutical Report II Issue25_December 2021 As Merck (NYSE:MRK) and Ridgeback Biotherapeutics sign on to a licensing deal to expand...
Medicare's National Coverage Determination Could Boost Chances of Limited Aduhelm Coverage
Biopharmaceutical Report II Issue24_September 2021 By opening a National Coverage Determination (NCD) on Biogen’s (NASDAQ:BIIB) Aduhelm...
Pepaxto's US Uptake to Stall in Multiple Myeloma Until FBA Provides Advice to Address Death Risk
Biopharmaceutical Report I Issue24_September 2021 Blood cancer oncologists are likely to hold back for now on using Oncopeptides’...
Innovations Forged in the COVID Crucible Will Reshape Medicine
Steve Usdin, Washington Editor Biopharmaceutical Report III Issue22_March 2021 The fight against COVID-19 is far from finished, but...
COVID-19 Long-Hauler Treatments Could Employ Repurposed Trial Endpoints to Prove Aptitude
Biopharmaceutical Report II Issue23_March 2021 COVID-19 long-hauler treatment trials will likely rely on established endpoints and trial...
bottom of page